期刊文献+

卵巢透明细胞癌CT、MRI影像特点的回顾性分析

下载PDF
导出
摘要 目的:探究与分析卵巢透明细胞癌CT、MRI影像特点,为其临床诊断与治疗提供必要的判断依据。方法:回顾性分析36例经手术与病理证实为OCCA患者的CT及MRI资料,其中18例CT平扫及增强扫描,17例MRI平扫及增强扫描,分析患者CT与MRI临床表现特征。结果:CT表现:18例患者CT平扫及增强扫描后,其中17例患者病灶均位于单侧,1列患者为双侧,最大径为8.2~26.5 cm,5例包膜不完整,4例肿块内可见分隔;囊性成分平扫CT值为18~28 HU,实性成分平扫CT值为29~51 HU,16例病灶呈类圆形,2例病灶呈分叶状。MRI表现:18例患者MRI平扫及增强扫描后,其中17例患者病灶均位于单侧,1列患者为双侧,最大径为8.5~29.1 cm,3例包膜不完整,3例肿块内可见分隔;囊性成分平扫CT值为18~28 HU,实性成分平扫CT值为29~51 HU,18例病灶呈类圆形,1例病灶呈分叶状。囊性成分1WI上信号复杂多变,包括低、等、高信号3类,T2WI多为高信号。实性成分T1WI以低信号为主,T2WI以信号为主,DWI为高信号。CT和MRI增强扫描后囊性成分无强化,分隔及实性成分动脉期强化明显,静脉期和延迟期持续强化。结论:OCCC的影像表现具有一定特征性,结合患者的临床表现,有助于医生对患者病症早期定位定性诊断。
作者 裴磊
出处 《中国妇幼健康研究》 2017年第S4期403-404,共2页 Chinese Journal of Woman and Child Health Research
  • 相关文献

参考文献6

二级参考文献94

  • 1Kobel M, KallogerSE, Garrick J, et al. A limited panel of immu-nomarkers can reliably distinguish between clear cell and high-(1):14-21.
  • 2Sugita S,Morishita Y, Kano J, et al. IGFBP-1 is expressed spe-cifically in ovarian clear cell adenocarcinoma. Histopathology,2011,58(5):729-738.
  • 3Wiegand KC, Shah SP, Al-Agha CM, et al. ARID1A mutationsin endometriosis-associated ovarian carcinomas. N Engl J Med,2010,363(16):1532-1543.
  • 4Kondi-Pafiti A, Papakonstantinou E, Iavazzo C, et al. Clinico-pathological characteristics of ovarian carcinomas associated withendometriosis. Arch Gynecol Obstet, 2012, 285(2) :479-483.
  • 5Ai BJ, Santos JL, Tinker A, et al. Exploring palliative treatmentoutcomes in women with advanced or recurrent ovarian clear cellcarcinoma. Gynecol Oncol, 2011, 122(1) :107-110.
  • 6DeLair D, Oliva E, Kobel M, et al. Morphologic spectrum of im-munohistochemically characterized clear cell carcinoma of the ova-ry :A study of 155 cases. Am J Surg Pathol, 2011,35(1) :36-44.
  • 7Markman M. Docetaxel plus trabectedin appears active in recur-rent or persistent ovarian and primary peritoneal cancer after upto three prior regimes : A phase 辽 study of the Gynecologic On-.cology Group. Gynecol Oncol, 2011,122(2) :462-463.
  • 8Mabuchi S, Kawase C, Altomare DA, et al. Vascular endotheli-al growth factor is a promising therapeutic target for the treat-ment of clear cell carcinoma of the ovary. Mol Cancer Ther,2010,9(8):2411-2422.
  • 9Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treat-ment of recurrent platinum-resistant ovarian cancer: Current andemerging therapies. Cancer Manag Res, 2011,3(3) :25-38.
  • 10Matsuoka Y, Ohtomo K, Araki T, et al. MR imaging of clearcell carcinoma of the ovary. Eur Radiol, 2001,11(6):946-951.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部